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Abstract 
Objective: To investigate the hypothesis of accelerated cognitive ageing in HIV positive 
individuals using longitudinal assessment of cognitive performance and quantitative MRI.  
Methods: We assessed a broad cognitive battery and quantitative MRI metrics (voxel based 
morphometry: VBM and diffusion tensor imaging: DTI) in asymptomatic HIV positive men 
who have sex with men (15 aged 20-40 years and 15 aged ≥50 years), and seronegative 
matched controls (nine aged 20-40 years and 16 aged ≥50 years).  
Results: Being HIV positive was associated with a greater decrease in executive function, 
and global cognition. Additionally, using DTI, the HIV Group had a greater increase in mean 
diffusivity, but we did not find group differences on volume change using VBM. With 
respect to the HIV by Age Group interaction, this was statistically significant for change in 
global cognition, with older HIV positive individuals showing greater global cognitive 
decline, but there were no significant interactions on other measures. Lastly, change in 
cognitive performance was correlated with change in the DTI measures, and this effect was 
stronger for the HIV positive participants.  
Conclusions: In the present study, we found some evidence for accelerated ageing in HIV 
with a statistically significant HIV by Age Group interaction in global cognition, although 
this interaction could not be explained by the imaging findings. Moreover, we also found that 
change in cognitive performance correlated with change in the DTI measures, and this effect 
was stronger for the HIV positive participants. This will need replication in larger studies 
using a similar follow-up delay.  
 
Keywords Ageing; Cognition; HIV; Neuroimaging; Longitudinal 
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Introduction 
Human Immunodeficiency Virus-1 (HIV-1) infection is characterized by 
inflammation of the CNS (1). Following the introduction of Highly Active Antiretroviral 
Therapy (HAART) the prognosis of HIV positive individuals in terms of morbidity and 
mortality has greatly improved (2). However, a substantial proportion of patients report mild 
cognitive problems, despite being on treatment (for review, see 3), with reported prevalence 
of HIV associated neurocognitive disorders in 30 to 50% of individuals (4, 5). This suggests 
the possibility that there is HIV related neuronal damage even in the subclinical stages of 
infection in people who are on stable HAART. 
With improved survival following HIV infection, one in four individuals living with 
HIV in the United Kingdom is now aged 50 or over (6). The combined influence of ageing 
and HIV is an important research area as there is evidence that HIV infection is associated 
with a higher prevalence of age-related conditions at a younger age (7). Moreover, it has been 
suggested that older age is associated with an increased risk of HIV associated 
neurocognitive disorders (8-10), indicating a possible effect of accelerated neurocognitive 
ageing (see 11). This was addressed in a recent review of behavioural and neuroimaging 
studies published between 2011 and 2014 (12). This revealed mixed findings, with 11 studies 
(six behavioural, five neuroimaging) supportive of the accelerated ageing hypothesis in HIV, 
and nine studies (four behavioural, five neuroimaging) not supportive. The authors suggested 
that methodological differences could explain the discrepancies, with studies that used global 
cognitive measures or neuroimaging techniques with poor specificity were less likely to find 
an interaction between HIV and age. However, as the majority (19 out of 20) of these studies 
were cross-sectional, this limits the extent to which accelerated neurocognitive ageing can be 
ascertained.  
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There have been fewer longitudinal studies that have investigated the impact of age 
and HIV on change in cognitive performance, but there is evidence for interacting effects of 
HIV and ageing. In one study, older HIV positive individuals showed a greater decline in 
executive function over five years than younger HIV positive individuals, whereas there was 
no effect of age on longitudinal performance for the seronegative controls (13). Similarly, 
individuals with HIV showed a greater one-year decline in verbal memory with increasing 
age, whereas the seronegative controls showed stable or improved performance with age (14). 
However, other longitudinal studies have not found interactive effects between HIV and age 
on cognitive change. For example, although HIV infection was associated with faster rates of 
cognitive decline in executive function, there was no evidence for accelerated decline with 
older age (15); and age was not a predictor of cognitive decline in a HIV cohort assessed 
regularly for up to five years (16). Instead, change in cognitive status was associated with 
disease severity, race, premorbid intelligence, current depressive symptoms, lifetime 
psychiatric diagnoses, and non-HIV-related comorbidities. Although this latter study 
highlighted the multifaceted risk factors for cognitive decline in HIV infection, it did not 
determine the degree to which HIV itself is linked to cognitive change in the absence of other 
risk factors.  
 MRI studies have further explored the impact of prolonged HIV exposure on brain 
structure. One such study found a greater increase in mean diffusivity (MD) in HIV positive 
individuals compared with seronegative controls, however the influence of age on HIV 
associated change in MD was not explored. The trajectories of volume change in HIV 
positive individuals and healthy controls have also been investigated (15). Here, the HIV 
group showed significantly greater change per year of infection than controls in terms of 
hippocampal and insula atrophy and significantly increased lateral ventricle volumes. There 
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was also significant acceleration of age-related trajectories of grey matter volume change in 
the thalamus and frontal, sensorimotor, and temporo-parietal neocortical regions.  
 In a previous study (17), we examined HIV positive and HIV negative older and 
younger individuals. All participants were asymptomatic with undetectable HIV viral loads, 
without medical or psychiatric comorbidity, or alcohol or substance misuse, and they had all 
been stable on HAART for at least six months prior to enrolment in the study. Comparison of 
the HIV groups did not show significant differences on the neuropsychological tests after 
Bonferroni correction. However, we found reduced grey matter volume on MRI in our HIV-
positive participants. Moreover, on FDG-PET and MRI based arterial spin labelling, (18) we 
found age-related reductions in the metabolic rate of glucose consumption and cerebral blood 
flow in frontal brain regions, and consistent (although small) reductions in the anterior 
cingulate in HIV. Across all measures, there were no significant HIV by Age Group 
interactions.  
In the present study, we re-assessed these participants, extending previous 
longitudinal investigations in the following ways: (i) all were on HAART, and all had 
undetectable viral load at baseline; (ii) all were Caucasian men who have sex with men; (iii) 
other confounding variables were controlled; and (iv) mean follow-up duration was 4.2 years. 
We investigated the interaction of HIV and age upon individual cognitive domains and global 
cognitive performance and we related these findings to concurrent MRI measures to see 
whether any cognitive deterioration was accompanied by associated changes in structural 
brain metrics. We hypothesised that: 
(i) There would be significant HIV by Age Group interaction in terms of change 
scores on cognitive testing; 
(ii) There would be significant HIV by Age Group interaction in terms of change in 
neuroimaging indexes; 
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(iii) There would be significant correlations between cognitive and neuroimaging 
changes. 
 
Methods 
Participant population 
Fifty-five participants (67%) from our previous cross-sectional study (17, 18) were 
included in the present study, with a mean time between assessments of 4.2 years (SD=0.8). 
Informed consent was obtained from all participants according to the Declaration of Helsinki 
and the study was approved by the East London Research Ethics Committee 3, NHS research 
ethics committee (Ref. 11/LO/0037). 
 All participants were Caucasian and self-identified as ‘men who have sex with men’. 
Baseline exclusion criteria were hepatitis B or C infection, any confounding neurological 
disorder, a history of head trauma with loss of consciousness greater than 10 minutes, and a 
history of harmful alcohol (>25 units of alcohol per week) or substance misuse. Additionally, 
the HIV positive participants were stable on HAART with an undetectable viral load (< 50 
copies/mL) and did not have a current or previous CNS-AIDS-condition. These criteria were 
met at follow-up, though one HIV positive individual reported harmful alcohol use and 
another had a viral load of 147 copies per mL. Excluding these two individuals did not 
influence the interpretation of any results; therefore, analyses based on the full sample have 
been reported. 
Medical and psychiatric evaluation 
Participants underwent a brief medical assessment and routine blood investigations 
which included HIV viral load, CD4 count (HIV group), conformation of HIV-negative status 
(control group), syphilis screen, hepatitis B and C, renal and liver function tests, bone and 
lipid profiles, and vitamin B12. The Beck Depression Inventory (19) and Beck Anxiety 
8 
 
 
Inventory (20), Profile of Mood States (McNair et al., 1981) were be used to assess mood 
state. The frequency of perceived memory difficulties was evaluated using the Prospective 
and Retrospective Memory Questionnaire (21). 
Cognitive assessment 
A wide range of cognitive tests was administered by trained psychologists (SC and 
BH) using standardised procedures. Raw scores were converted to z-scores using baseline 
seronegative findings, which were then averaged to form five cognitive domain scores; 
executive function, complex attention, learning and memory, language, and perceptual motor 
function. The tasks that were included in each domain can be found in Table 1. Change 
scores were generated by subtracting the baseline from follow-up z-scores. 
Table 1 about here 
MRI protocol 
Scans were acquired on a GE SIGNA 3T MR scanner (General Electric, Chicago, 
USA) at the Centre for Neuroimaging Sciences, King’s College London using the same 
imaging protocol as the baseline study (17).  
Image processing 
Voxel-based morphometry (VBM) processing. Datasets were pre-processed and 
analysed using SPM12 (Wellcome Department of Cognitive Neurology, London, UK, 
http://fil.ion.ucl.ac.uk). As the original study used XBAM (22), we first reanalysed the 
baseline data using the DARTEL toolbox (23, 24) in SPM12 to confirm that results were 
consistent with those previously reported (17). 
Longitudinal VBM analysis. Baseline and follow-up scans were submitted to a 
pairwise longitudinal registration (25) using SPM12. This procedure generates normalised 
images of grey matter volume loss between scan 1 and scan 2. These images were then used 
for statistical analysis in which a two-way (HIV status by Age Group) ANOVA was fitted at 
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each voxel in standard space. Further detail of the analysis procedure can be found in the 
Supplemental Digital Content. 
Diffusion Tensor Imaging (DTI) analysis. Datasets were pre-processed and 
analysed using tools from the Oxford Centre for Functional MRI of the Brain Software 
Library (FSL; http:/www.fmrib.ox.ac.uk/fsl). One older control was excluded following 
manual inspection for artefacts. Pre-processing used a standard multi-step procedure that 
involved correction for motion and eddy-currents (26), extraction of non-brain tissue (27), 
and fitting a tensor model to the raw diffusion weighted images. Maps of the directionality 
(Fractional anisotropy: FA) and the extent (MD) of diffusion were then generated. As the 
present analysis method differed from that used at baseline (XBAM; 22), we first reanalysed 
the baseline scans using tract based spatial statistics (TBSS: 28). The results were consistent 
with those reported in the original paper (17). 
Longitudinal DTI analysis. Longitudinal effects were analysed using a modified 
longitudinal TBSS protocol based on (29), which was designed to optimise intra-subject 
registration and account for residual variation due to change of head placement and MRI 
scanner drift between sessions. This protocol produced skeletonised maps of the difference in 
FA or MD between the two scans. Further detail of the analysis procedure can be found in the 
Supplemental Digital Content. Analysis was performed using permutation-based 
nonparametric cluster inference (Randomise, implemented in FSL). A two-way (HIV status 
by Age Group) ANCOVA was applied using 10,000 permutations with time between scans 
added as a covariate. For each statistical test, results were corrected for multiple comparisons 
using Threshold-Free Cluster Enhancement (TFCE;  30).  
 
Results 
Clinical and psychiatric evaluation 
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Table 2 shows the characteristics of study participants. The younger HIV positive 
participants were significantly older than the younger seronegative group. No other 
differences were evident between these younger groups. Similarly the older HIV positive 
participants did not differ from the older seronegative group. In particular, there were no 
group differences on anxiety or depression measures in either the younger or older 
participants. Looking at HIV-related variables, the older and younger HIV positive 
individuals did not differ significantly on current t(30)=0.43,p=.673,d=0.16 or nadir 
t(28)=0.49, p=.628, d=0.19 CD4 count. The older HIV participants had a longer average 
number of years since diagnosis than the younger participants t(28)=3.26, p=.003, d=1.19, 
but treatment duration did not reach statistical significance, t(28)=1.97, p=.059, d=0.72.  
   Table 2 approx here 
Group difference analysis for the neuropsychological assessment 
HIV status. There was a statistically significant effect of HIV status on change in 
executive function F(1,55)=6.77, p=.012, d=0.70 and global cognition, F(1,55)=7.89, p=.007, 
d=.76. The results suggest that the HIV group (executive function, M= -0.40, SD=0.75; global 
cognition, M= -0.12, SD=0.33) displayed a greater reduction in z-scores than the seronegative 
controls (executive function, M=0.06, SD=0.44; global cognition, M=0.08, SD=0.19). 
Differences were non-significant for the other cognitive domains; in each of these, 
F(1,55)≤2.71, p≥.106, d≤0.45. 
Age. There was a statistically significant  effect of Age Group on change in complex 
attention, F(1,55)=6.70, p=.011, d=0.72, perceptual-motor function, F(1,55)=5.83, p=.020, 
d=0.66 and  global cognition, F(1,55)=6.21, p=.016, d=0.68, Here, the older participants 
showed a greater reduction in z-scores than the younger participants. The effect of age was 
not significant for the other cognitive domains, in each of these F(1,55)≤2.41, p≥.127, 
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d≤0.36. Critically, this included executive function, which was the only domain to show an 
effect of HIV status.  
HIV status by Age Group interaction. One important question was whether the 
results were suggestive of accelerated ageing with HIV. Here, we were interested in whether 
there was a significant HIV by Age Group interaction. This was only significant for change in 
global cognition, F(1,55)=4.39, p=.041, where there was a larger difference in  global change 
scores between  the older HIV positive and negative participants, t(31)=3.25, p=.003, d=1.17 
than the younger participants, t(24)=0.54, p=.598, d=0.23. These cognitive findings are 
summarised in Figure 1. 
Figure 1 approx here 
Neuroimaging findings  
HIV status. Using VBM, no regions reached family-wise error corrected significance 
for the main effect of HIV status on rate of grey matter volume change. On the DTI metrics, 
there was no significant main effect of HIV status on change in FA. There was, however, a 
significant difference for change in MD, with the HIV group showing a greater increase in 
MD than the seronegative controls in the corpus collosum, the right posterior corona radiata 
and right posterior thalamic radiation (see Figure 2).  
Figure 2 approx here 
Age. On the VBM analysis, there was no effect of age on rate of change in regional 
grey matter volume (family-wise error corrected p<.05). With respect to the DTI measures, 
older participants showed a greater decrease in FA than the younger group in the right 
anterior corona radiata, right anterior limb of the internal capsule, and the right genu and 
splenium of the corpus callosum. There were also significant age effects on change MD, in 
widespread regions bilaterally (See Figure 3). 
Figure 3 approx here 
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HIV status by Age Group interaction. No significant interactions were identified 
between HIV status and age group for change in grey matter volume, change in FA, or 
change in MD.  
Correlations between HIV, neuroimaging, and neuropsychological variables.  
To allow comparison between the neuropsychological and neuroimaging variables, 
atlas-based regions of interest (frontal white matter and the genu, body, and splenium of the 
corpus callosum) were created in FSL using the JHU ICBM-DTI-81 White-Matter Labels 
Atlas (http://cmrm.med.jhmi.edu). FA and MD values were extracted from the baseline and 
follow-up scans and were then subtracted to generate FADIFF and MDDIFF scores.  
A series of hierarchical multiple regression models were used to explore the influence 
of HIV status and FADIFF  or MDDIFF on global cognitive change. Step 1 adjusted for 
covariates of age group, IQ, and time between assessments. At Step 2, the primary effects of 
HIV status and FADIFF or MDDIFF were added, and at Step 3, a HIV status x FADIFF /MDDIFF 
cross-product interaction term was entered. Here, we were interested in whether the 
interaction term significantly added to the variance (Δr2) explained in global cognitive 
change, which would suggest the strength of the association between change in the DTI 
metrics and change in cognition varied as a function of HIV status.  
The results of the hierarchical regressions can be found in Table 3. Adding HIV status 
and FADIFF or MDDIFF added to the prediction of global cognitive change, with shared 
variances ranging from 26 to 37%. Importantly, at Step 3, the HIV status x FADIFF or HIV x 
MDDIFF interaction terms were significant for the majority of regions (all except FADIFF in the 
body of the corpus callosum). The interaction explained a further 7 to 15% of the variance in 
global cognitive change. This association was further explored separately in the patient and 
control groups. In the HIV group, worsening cognitive performance was associated with a 
greater increase in MD (β≤-.531, p<.01) and a greater decrease in FA (β≥.483, p<.01), 
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whereas these relationships were of a smaller magnitude and were non-significant in the 
seronegative group (MD, β≥-.214, p≥.442; FA, β≤.429, p≥.060). Lastly, in the HIV positive 
participants we assessed whether the association between change in DTI metrics and change 
in cognitive performance was modified by age group. The Age by DTI metric cross-product 
interaction was non-significant for all measures. 
Table 3 approx here 
 
Discussion 
This study investigated longitudinal change in cognitive performance and quantitative 
MRI findings in HIV positive individuals. We hypothesised that there would be an interaction 
between age group and HIV status, supporting the notion of accelerated ageing in HIV (11). 
In our small sample, we found that the HIV positive participants had a greater global 
cognitive decline than their seronegative controls and this was exacerbated in the older age 
group. However, when the cognitive domains were analysed separately, there were no 
significant HIV by Age Group interactions. On neuroimaging measures, HIV infection and 
older age were each associated with a greater increase in MD, but there were no significant 
HIV by Age Group interactions. Lastly, change in cognitive performance correlated with 
change in DTI measures, and this effect was stronger for the HIV positive participants but did 
not differ between the age groups.  
It is of note that HIV and Age Group appeared to affect different components of 
cognitive function. There was a statistically significant effect of HIV on executive function, 
whereas age group influenced domains that involved speed of performance (i.e., change in 
complex attention and perceptual-motor function). With respect to executive function, 
younger HIV positive individuals, as well as older ones, showed worse performance (in terms 
of change scores), relative to controls. This suggests it was HIV infection itself that 
14 
 
 
influenced this domain rather than an effect of age group. While the present results are 
broadly consistent with previous neuropsychological findings (e.g., 15), we must 
acknowledge that caution is needed in interpreting these cognitive findings because of the 
small sample size in our groups.  
The VBM results showed no influence of HIV or age group on grey matter volume, 
and no interaction between HIV status and age group, suggesting that the groups showed an 
equivalent rate of change in volume over time. At baseline, we found reduced grey matter 
volume in a cluster encompassing the medial and superior frontal-gyrus in the HIV positive 
participants (17). Longitudinally, we did not find evidence that this had progressed (although 
this might perhaps have reflected the relatively young age of our older group, with a 
minimum age of 50 years at baseline). One possible interpretation of this particular finding 
would be that HIV has an effect on grey matter volume early in the disease process, for 
example pre-treatment. By contrast, one previous study (15) did find evidence of HIV by Age 
effects on regional grey matter in a sample which was larger than ours, but less highly 
selected to exclude confounding factors. 
Our DTI findings highlighted the importance of longitudinal evaluation in HIV, as 
baseline analysis in this sample did not find any differences on either MD or FA (17), but in 
the present analysis, we found that both HIV infection and age group were associated with a 
greater longitudinal increase in MD. In other words, HIV infection was associated with 
greater cerebral white matter damage through time, even in patients who had a good 
treatment response to HAART and no significant cerebrovascular risk factors. This may 
reflect persistent immune activation and neuro-inflammation (31, 32). The present results 
also suggest that the group differences in DTI change scores might be clinically relevant, as 
regression analysis indicated that cognitive performance changed in conjunction with DTI 
change, and that this association was stronger for the HIV group. Thus, the HIV positive 
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patients with the greatest increase in MD, or decrease in FA, showed the greatest decline in 
cognitive performance (in terms of change scores). There have been few other longitudinal 
DTI studies in persons with HIV, but our results are in line with a previous study that showed 
an HIV related increase in MD in the genu of the corpus callosum and a correlation between 
change in global cognition and DTI measures in the corpus callosum in HIV positive 
individuals (33). We have extended this from one year to a longer follow-up duration and 
using voxel-based procedures, we identified more widespread longitudinal changes. We also 
showed that older age was associated with a greater increase in MD and decrease in FA. 
However, in the present sample, there were no HIV by age group interactions, and similar 
DTI-cognitive associations were evident in both the younger and older HIV positive 
participants. 
Our study had a number of strengths. It had a relatively long follow-up, with a mean 
duration of 4.2 years. It was well controlled in terms of comorbidities, and drug and alcohol 
use, and the HIV positive group was asymptomatic and stable on HAART. We also carefully 
recruited a control group with a similar sociodemographic background who were well 
matched on age, IQ, and education. We can, therefore, be confident that the findings are 
likely to be the result of HIV infection and not of other confounding factors. There were, 
however, some limitations. Sample sizes were relatively small as we were limited by the size 
of the original sample. Moreover, the detail of our neuropsychological assessment, the range 
of our imaging protocols (which included positron emission tomography at baseline), and the 
duration of our follow-up, may have affected the attrition rate, which was imbalanced across 
the groups. The findings should be corroborated in larger samples, allowing for variability in 
other important factors that can affect cognition such as anxiety and depression scores. 
In conclusion, we found independent (main) effects of both HIV and age group on 
longitudinal change in cognitive performance and change through time in mean diffusivity 
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using DTI, but not an effect on volumetrics.  The results suggested accelerated ageing in 
HIV, in that there was a significant HIV by Age Group interaction for change in global 
cognition. Being HIV positive and older was associated with a worsening in overall cognitive 
performance. However, this interaction could not be explained by the imaging findings, as 
there were no significant interactions for any of the imaging metrics. Further work is needed 
to look at other biological factors that could explain change in overall cognitive performance 
in HIV, including metabolic findings and treatment effects. 
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Table 1: The cognitive test battery 
Executive function Complex attention 
Trail Making Test B (34),  Trail Making Test A (34) 
Modified Cord Sorting Test (35),  Paced Serial Addition Test (36)  
WAIS III Letter number sequencing (37) WAIS III Symbol search (37) 
WAIS III Matrix reasoning (37) WAIS III Digit span (37) 
 WAIS III Digit-symbol coding (37) 
Learning and memory Language  
WAIS-R Logical Memory I and II (38)   WAIS III Vocabulary (37) 
WAIS-R Visual Reproduction I and II (38) WAIS III Similarities(37) 
Rey Auditory Verbal Learning Test (39)  McKenna Graded Naming Test (40) 
Word-pair and single-word recognition  
(41) 
Controlled Oral Word Association Test 
(42) 
Perceptual motor function  
Grooved Pegboard Test (43).   
WIAS III Block design (37)  
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Table 2: Demographic and clinical variables  
 HIV-1 positive HIV-1 seronegative 
 Older Young Older Young 
Sample size 15 15 16 9 
Age 
 
62.5 (5.5) 39.7 (4.0) 59.4 (6.5) 34.2 (5.0) 
IQ     
NART 117.14 (6.50) 112.93 (9.27) 118.86 (6.50) 117.67 (6.67) 
WAIS-III FSIQ 119.00 
(13.35) 
118.27 (8.54) 125.06 (9.21) 121.89 
(14.79) 
Mood     
Depression 6.40 (6.22) 5.53 (4.60) 5.25 (3.36) 3.22 (3.23) 
Δ Depression a -2.00 (5.26) -1.07 (5.44) -1.19 (3.14) -0.38 (2.00) 
Anxiety 6.80 (5.26) 4.13 (6.16) 3.25 (3.75) 3.56 (2.46) 
Δ Anxiety a -0.73 (5.47) -0.60 (6.83) 1.31 (7.07) -1.13 (1.55) 
POMS tension 4.36 (3.93) 2.85 (2.15) 3.72 (2.52) 3.15 (5.34) 
POMS depression 1.79 (2.49) 3.00 (4.36) 1.00 (1.69) 2.86 (5.98) 
POMS anger 0.64 (1.60) 1.85 (1.86) 1.20 (1.32) 0.71 (1.89) 
POMS vigour 19.79 (9.07) 15.07 (5.87) 18.40 (4.42) 17.43 (5.59) 
POMS fatigue 3.21 (3.29) 3.84 (5.53) 3.20 (3.76) 2.57 (3.64) 
POMS confusion 3.29 (2.13) 3.92 (3.14) 3.27 (2.19) 3.57 (2.15) 
PRMQ prospective 
b 
50.67 (7.84) 52.80 (8.55) 54.50 (7.36) 60.00 (10.24) 
PRMQ retrospective 
b 
52.60 (7.91) 57.27 (7.79) 57.50 (6.26) 62.11 (7.42) 
HIV variables     
CD4 cells/ mm
3
 711.92 
(278.91) 
771.47 
(352.53) 
- - 
Nadir CD4 cells/ mm
3
 183.20 
(101.75) 
167.15 
(96.40) 
- - 
Years since diagnosis
 
16.67 (6.59) 12.40 (5.22) - - 
Years HAART 
treatment 
 
12.53 (3.68) 8.60 (2.87) - - 
 
Notes: PRMQ=Prospective and retrospective memory questionnaire; POMS=Profile of 
mood states. 
a 
 baseline – follow-up, b t-scores.
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Table 3: Hierarchical regression analysis predicting change in global cognitive performance from change in DTI metrics. 
 FA Frontal MD Frontal FA CC Body MD CC Body FA CC Genu MD CC Genu FA CC Splenium MD CC Splenium 
 β Δr2 Β Δr2 β Δr2 β Δr2 β Δr2 β Δr2 β Δr2 β Δr2 
Step 2                 
 HIV -.374
**
  -.346
**
  -.366
**
  -.377
**
  -.388
**
  -.370
**
  -.241
*
  -.353
*
  
 DTI 
metric 
.400
**
 .264
**
 -.368
*
 .222
**
 .452
**
 .318
**
 -.502
**
 .316
**
 .356
**
 .233
**
 -.332
*
 .213
**
 .445
**
 .285
**
 -.313
*
 .203
**
 
Step 3                 
 HIV x 
DTI 
.351
*
 .062
*
 -.512
**
 .110
**
 .178 .006 -681
**
 .148
**
 .542
**
 .123
**
 -.512
**
 .137
**
 .496
*
 .061
*
 -.613
**
 .123
**
 
Note: Step 1 Δr2=.140, p=.083; Age β= -.278, p=.059; NART error score, β= -.328, p=.038; Time difference, β= .088, p=.565. 
DTI = diffusion tensor imaging; FA = fractional anisotropy; MD = mean diffusivity; CC = corpus callosum.  
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Figure Captions: 
Figure 1: Mean (standard error) change in z-score for each cognitive domain. 
Notes: Change scores were generated using baseline minus follow-up. Negative values 
therefore represent a decline in performance whilst positive values represent an improvement. 
(1) Main effect of HIV status; (2) Main effect of age group; (3) HIV by Age Group 
interaction (p<.05). 
 
Figure 2: The influence of HIV status on change in mean diffusivity (MD). 
Notes: Regions in which the HIV group showed a greater increase in MD (red-yellow) than 
the seronegative controls. This includes the genu and splenium of the corpus callosum, right 
posterior corona radiata, and right posterior thalamic radiation. 
 
Figure 3: The influence of age on change in mean diffusivity (MD) and fractional anisotropy 
(FA) 
Notes: Regions in which older participants show a greater decreased in FA (blue) and greater 
increase in MD (red-yellow) than younger participants. This includes change in FA in the 
right anterior corona radiata, right anterior limb of the internal capsule, and the right genu and 
splenium of the corpus callosum and change in MD in widespread regions.  
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Figure 2: The influence of HIV status on change in mean diffusivity (MD). 
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Figure 3: The influence of age on change in mean diffusivity (MD) and fractional anisotropy (FA) 
 
 
 
 
